GreenLight Biosciences, Inc., a Medford, Mass.-based developer of a platform to develop a portfolio of RNA-based products for use in agriculture, completed a $18m Series D round of financing.
The round was led by Fall Line Capital, with participation from S2G Ventures, Lewis and Clark Ventures, and Macro Capital Investments and existing investors, including Kodiak Venture Partners, MLSCF, Syngenta Ventures and others.
The company intends to use the funds to accelerate development and field testing of a number of dsRNA molecules targeting insect and viral pests in high-value crops and build up the team.
Led by Andrey J. Zarur, Ph.D., Co-Founder and Chief Executive Officer, GreenLight leverages its Cell-Free Bioprocessing® platform to develop a portfolio of RNA-based products for use in agriculture, to directly address the target pest, while completely sparing beneficial and benign organisms, with minimal impact to the environment.
The company is also developing further RNA offerings in the areas of public health, vaccine development and human therapeutics.